Inebilizumab, a CD19+ B-cell–depleting monoclonal antibody, has shown promising results in improving function and reducing disease severity in patients with generalized myasthenia gravis, as observed in the randomized, placebo-controlled Myasthenia Gravis Inebilizumab Trial (MINT).

The trial demonstrated significant benefit in improving Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, suggesting the potential efficacy of targeting CD19+ B cells in depleting antibody-secreting cells. The trial also highlighted the need for further data to confirm the long-term safety and efficacy of inebilizumab.

Source: New England Journal of Medicine